Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio, D. W. East, M. B. Troner, Charles Vogel

Research output: Contribution to journal › Article

23 Citations (Scopus)

Abstract

The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

Original languageEnglish
Pages (from-to)2113-2115
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number12
StatePublished - Dec 1 1978

Fingerprint

Vinblastine
Mitomycin
Appointments and Schedules
Breast Neoplasms
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. / Denefrio, J. M.; East, D. W.; Troner, M. B.; Vogel, Charles.

In: Cancer Treatment Reports, Vol. 62, No. 12, 01.12.1978, p. 2113-2115.

Research output: Contribution to journal › Article

Denefrio, JM, East, DW, Troner, MB & Vogel, C 1978, 'Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy', Cancer Treatment Reports, vol. 62, no. 12, pp. 2113-2115.
Denefrio JM, East DW, Troner MB, Vogel C. Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. Cancer Treatment Reports. 1978 Dec 1;62(12):2113-2115.
Denefrio, J. M. ; East, D. W. ; Troner, M. B. ; Vogel, Charles. / Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 12. pp. 2113-2115.
@article{dd26e8cd7d0548acb18d9595d823fa7c,
title = "Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy",
abstract = "The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.",
author = "Denefrio, {J. M.} and East, {D. W.} and Troner, {M. B.} and Charles Vogel",
year = "1978",
month = "12",
day = "1",
language = "English",
volume = "62",
pages = "2113--2115",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

AU - Denefrio, J. M.

AU - East, D. W.

AU - Troner, M. B.

AU - Vogel, Charles

PY - 1978/12/1

Y1 - 1978/12/1

N2 - The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

AB - The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=0018236249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018236249&partnerID=8YFLogxK

M3 - Article

C2 - 751719

AN - SCOPUS:0018236249

VL - 62

SP - 2113

EP - 2115

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -

Access to Document